To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Phase 2CompletedNCT00141414

Pfizer82 enrolled

Overview

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Epilepsy, Partial

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have met the inclusion criteria for preceding double-blind study. * Have received double-blind study medication and wish to receive open-label pregabalin. Exclusion Criteria: * Pregnant or considering becoming pregnant. * Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.

Locations (25)

Pfizer Investigational Site

Little Rock, Arkansas, United States

Outcomes

Primary Outcomes

Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.